Cargando…
Beneficial effects of curtailing immune susceptibility in an Alzheimer’s disease model
BACKGROUND: Currently, there are no effective therapeutic options for Alzheimer’s disease, the most common, multifactorial form of dementia, characterized by anomalous amyloid accumulation in the brain. Growing evidence points to neuroinflammation as a major promoter of AD. We have previously shown...
Autores principales: | Di Benedetto, Giulia, Burgaletto, Chiara, Carta, Anna R., Saccone, Salvatore, Lempereur, Laurence, Mulas, Giovanna, Loreto, Carla, Bernardini, Renato, Cantarella, Giuseppina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693231/ https://www.ncbi.nlm.nih.gov/pubmed/31409354 http://dx.doi.org/10.1186/s12974-019-1554-9 |
Ejemplares similares
-
Role of Microglia and Astrocytes in Alzheimer’s Disease: From Neuroinflammation to Ca(2+) Homeostasis Dysregulation
por: Di Benedetto, Giulia, et al.
Publicado: (2022) -
Repositioning of Immunomodulators: A Ray of Hope for Alzheimer’s Disease?
por: Munafò, Antonio, et al.
Publicado: (2020) -
Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer’s disease
por: Burgaletto, Chiara, et al.
Publicado: (2021) -
The immune system on the TRAIL of Alzheimer’s disease
por: Burgaletto, Chiara, et al.
Publicado: (2020) -
Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer’s Disease
por: Musumeci, Teresa, et al.
Publicado: (2022)